T1	PROC 1020 1027	tratado
#1	AnnotatorNotes T1	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T2	PROC 186 222	Fase II, muticéntrico, de solo brazo
T3	CHEM 83 92	sirolimus
#2	AnnotatorNotes T3	C0072980; sirolimus; Antibiotic · Organic Chemical
T4	CHEM 95 109	ciclofosfamida
#3	AnnotatorNotes T4	C0010583; cyclophosphamide; Organic Chemical · Pharmacologic Substance
T5	DISO 127 140	condrosarcoma
#4	AnnotatorNotes T5	C0008479; Chondrosarcoma; Neoplastic Process
T6	DISO 143 162	liposarcoma mixoide
#5	AnnotatorNotes T6	C0206634; Liposarcoma, Myxoid; Neoplastic Process
T7	PROC 229 248	evaluar la eficacia
#6	AnnotatorNotes T7	C1707887; Efficacy Study; Research Activity
T8	PROC 253 264	tratamiento
#7	AnnotatorNotes T8	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T9	CHEM 281 295	ciclofosfamida
#8	AnnotatorNotes T9	C0010583; cyclophosphamide; Organic Chemical · Pharmacologic Substance
T10	DISO 299 312	condrosarcoma
#9	AnnotatorNotes T10	C0008479; Chondrosarcoma; Neoplastic Process
T11	DISO 315 334	liposarcoma mixoide
#10	AnnotatorNotes T11	C0206634; Liposarcoma, Myxoid; Neoplastic Process
T12	DISO 385 398	Condrosarcoma
#11	AnnotatorNotes T12	C0008479; Chondrosarcoma; Neoplastic Process
T13	DISO 399 418	Liposarcoma mixoide
#12	AnnotatorNotes T13	C0206634; Liposarcoma, Myxoid; Neoplastic Process
T14	DISO 445 458	Condrosarcoma
#13	AnnotatorNotes T14	C0008479; Chondrosarcoma; Neoplastic Process
T15	DISO 472 491	Liposarcoma mixoide
#14	AnnotatorNotes T15	C0206634; Liposarcoma, Myxoid; Neoplastic Process
T16	DISO 496 504	mutación
T17	DISO 531 574	Condrosarcoma mesenquimal o desdiferenciado
T18	DISO 603 616	Condrosarcoma
#15	AnnotatorNotes T18	C0008479; Chondrosarcoma; Neoplastic Process
T19	PROC 645 664	anatomía patológica
#16	AnnotatorNotes T19	C0200712; Anatomic pathology procedure; Laboratory Procedure
T20	DISO 671 690	liposarcoma mixoide
#17	AnnotatorNotes T20	C0206634; Liposarcoma, Myxoid; Neoplastic Process
T21	CHEM 1032 1049	inhibidor de mTOR
#18	AnnotatorNotes T21	C2746052; MTOR Inhibitors; Pharmacologic Substance
T22	DISO 1053 1060	Alergia
#19	AnnotatorNotes T22	C1527304; Allergic Reaction; Pathologic Function
T23	CHEM 1072 1086	ciclofosfamida
#20	AnnotatorNotes T23	C0010583; cyclophosphamide; Organic Chemical · Pharmacologic Substance
T24	DISO 1126 1132	Lesión
#21	AnnotatorNotes T24	C0221198; Lesion; Finding
T25	PROC 1192 1205	Cirugía mayor
#22	AnnotatorNotes T25	C0679637; major surgery; Therapeutic or Preventive Procedure
T26	PROC 1300 1313	diagnosticado
#23	AnnotatorNotes T26	C0011900; Diagnosis; Diagnostic Procedure
T27	CHEM 269 278	sirolimus
#24	AnnotatorNotes T27	C0072980; sirolimus; Antibiotic · Organic Chemical
T28	DISO 349 360	metastásico
#25	AnnotatorNotes T28	C0027627; Neoplasm Metastasis; Neoplastic Process | C4255448; Metastasis; Pathologic Function
T29	PROC 1249 1260	tratamiento
#26	AnnotatorNotes T29	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T30	DISO 695 703	mutación
T31	PROC 745 764	anatomía patológica
#27	AnnotatorNotes T31	C0200712; Anatomic pathology procedure; Laboratory Procedure
T32	PROC 829 848	anatomía patológica
#28	AnnotatorNotes T32	C0200712; Anatomic pathology procedure; Laboratory Procedure
T33	DISO 1263 1299	Virus de la inmunodeficiencia humana
T34	DISO 770 813	condrosarcoma mesenquimal o desdiferenciado
T35	Date 13 17	2013
T36	LIVB 113 122	pacientes
#29	AnnotatorNotes T36	C0030705; Patients; Patient or Disabled Group
T37	Neg_cue 514 525	ausencia de
T38	Neg_cue 713 724	ausencia de
T39	LIVB 852 861	Pacientes
#30	AnnotatorNotes T39	C0030705; Patients; Patient or Disabled Group
T40	Age 866 879	18 años o más
T41	Duration 959 978	los últimos 6 meses
T42	Duration 1107 1122	menor a 3 meses
T44	Duration 1209 1228	los últimos 4 meses
T46	GENE 505 511	PIK3CA
#31	AnnotatorNotes T46	C1335212; PIK3CA gene; Gene or Genome
T47	GENE 526 530	PTEN
#32	AnnotatorNotes T47	C0694888; PTEN gene; Gene or Genome
T48	GENE 725 729	PTEN
#33	AnnotatorNotes T48	C0694888; PTEN gene; Gene or Genome
T49	GENE 704 710	PIK3CA
#34	AnnotatorNotes T49	C1335212; PIK3CA gene; Gene or Genome
A1	Assertion T47 Negated
A2	Assertion T48 Negated
A3	Status T1 History_of
A4	Status T21 History_of
A5	Status T22 History_of
A6	Status T25 History_of
#35	AnnotatorNotes T16	C1705285; Mutation Abnormality; Cell or Molecular Dysfunction
#36	AnnotatorNotes T30	C1705285; Mutation Abnormality; Cell or Molecular Dysfunction
#37	AnnotatorNotes T17	C0862878; Dedifferentiated chondrosarcoma; Neoplastic Process + C0206637; Mesenchymal Chondrosarcoma; Neoplastic Process 
#38	AnnotatorNotes T34	C0862878; Dedifferentiated chondrosarcoma; Neoplastic Process + C0206637; Mesenchymal Chondrosarcoma; Neoplastic Process 
#39	AnnotatorNotes T33	C0458074; Human immunodeficiency virus (HIV) status; Finding
T43	Quantifier_or_Qualifier 1136 1143	medible
A7	Assertion T43 Negated
T45	Neg_cue 1133 1135	no
T50	Observation 883 905	Progresión radiológica
T51	CONC 945 955	RECIST 1.1
#40	AnnotatorNotes T51	C1709926; Response Evaluation Criteria in Solid Tumors; Intellectual Product
R1	Overlap Arg1:T50 Arg2:T41	
R2	Used_for Arg1:T21 Arg2:T1	
R3	Causes Arg1:T23 Arg2:T22	
T52	CONC 1089 1106	Esperanza de vida
#41	AnnotatorNotes T52	C0023671; Life Expectancy; Group Attribute
R4	Has_Duration_or_Interval Arg1:T52 Arg2:T42	
R5	Negation Arg1:T45 Arg2:T43	
#42	AnnotatorNotes T43	C1513040; Measurable; Functional Concept
R6	Has_Quantifier_or_Qualifier Arg1:T24 Arg2:T43	
T53	CONC 1162 1172	RECIST 1.1
#43	AnnotatorNotes T53	C1709926; Response Evaluation Criteria in Solid Tumors; Intellectual Product
R7	Overlap Arg1:T25 Arg2:T44	
R8	Before Arg1:T25 Arg2:T29	
R9	Combined_with Arg1:T3 Arg2:T4	
R10	Overlap Arg1:T5 Arg2:T6	
R11	Experiences Arg1:T36 Arg2:T3	
R12	Experiences Arg1:T36 Arg2:T5	
R13	Experiences Arg1:T36 Arg2:T6	
R14	Used_for Arg1:T27 Arg2:T8	
R15	Combined_with Arg1:T27 Arg2:T9	
R16	Before Arg1:T11 Arg2:T28	
T54	Observation 335 346	irresecable
#44	AnnotatorNotes T54	C4039777; Tumor surgically unresectable; Finding
R17	Has_Quantifier_or_Qualifier Arg1:T11 Arg2:T54	
R18	Overlap Arg1:T15 Arg2:T16	
R19	Location_of Arg1:T46 Arg2:T16	
R20	Overlap Arg1:T16 Arg2:T47	
R21	Negation Arg1:T37 Arg2:T47	
R23	Overlap Arg1:T20 Arg2:T30	
R24	Location_of Arg1:T49 Arg2:T30	
R25	Overlap Arg1:T30 Arg2:T48	
R26	Negation Arg1:T38 Arg2:T48	
R29	Has_Age Arg1:T39 Arg2:T40	
T55	CONC 1182 1186	ECOG
#45	AnnotatorNotes T55	C1520224; ECOG performance status; Intellectual Product
T56	Result_or_Value 1187 1189	>2
R30	Has_Result_or_Value Arg1:T55 Arg2:T56	
R31	Overlap Arg1:T10 Arg2:T11	
#46	AnnotatorNotes T50	C5236986; Radiographic Progressive Disease; Finding
A8	Experiencer T39 Patient
A9	Experiencer T36 Patient
